Experimental and real-world evidence supporting the computational repurposing of bumetanide for APOE4-related Alzheimer’s disease-Reference-Cited by-同舟云学术

Experimental and real-world evidence supporting the computational repurposing of bumetanide for APOE4-related Alzheimer’s disease

Published:2021-10 Issue:10 Volume:1 Page:932-947
ISSN:2662-8465
Container-title:Nature Aging
language:en
Short-container-title:Nat Aging

Author:

Taubes Alice,Nova Phil,Zalocusky Kelly A.,Kosti Idit^ORCID,Bicak Mesude,Zilberter Misha Y.^ORCID,Hao Yanxia,Yoon Seo Yeon,Oskotsky Tomiko^ORCID,Pineda Silvia,Chen Bin^ORCID,Aery Jones Emily A.,Choudhary Krishna^ORCID,Grone Brian,Balestra Maureen E.,Chaudhry Fayzan,Paranjpe Ishan,De Freitas Jessica,Koutsodendris Nicole,Chen Nuo,Wang Celine,Chang William,An Alice,Glicksberg Benjamin S.^ORCID,Sirota Marina^ORCID,Huang Yadong^ORCID

Funder

U.S. Department of Health & Human Services | NIH | National Institute on Aging

U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences

U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences

Publisher

Springer Science and Business Media LLC

Subject

Pulmonary and Respiratory Medicine,Pediatrics, Perinatology, and Child Health

Link

https://www.nature.com/articles/s43587-021-00122-7.pdf

Reference64 articles.

1. Golde, T. E., Schneider, L. S. & Koo, E. H. Anti-Aβ therapeutics in Alzheimer’s disease: the need for a paradigm shift. Neuron 69, 203–213 (2011).